NovoCure Files 8-K: Officer Changes & Financials
Ticker: NVCR · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, officer-changes
Related Tickers: NVCR
TL;DR
NovoCure dropped an 8-K on 11/24 - check for officer changes and financials.
AI Summary
NovoCure Limited filed an 8-K on November 24, 2025, reporting changes in directors or officers, Regulation FD disclosures, and financial statements. The filing details the company's principal executive offices located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
Why It Matters
This 8-K filing provides updates on NovoCure's corporate governance and financial reporting, which are crucial for investors to assess the company's stability and performance.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate updates and financial reporting, not indicating any immediate operational or financial distress.
Key Numbers
- 11/24/2025 — Date of Report (Earliest event reported)
- 12/31 — Fiscal Year End (Company's fiscal year end)
Key Players & Entities
- NovoCure Limited (company) — Registrant
- Jersey (company) — Jurisdiction of incorporation
- St. Helier (company) — City of Principal Executive Offices
FAQ
What specific changes were reported regarding directors or officers?
The filing indicates 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these changes are not provided in the excerpt.
What is the primary business address of NovoCure Limited?
The principal executive offices are located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
What is the SEC file number for NovoCure Limited?
The SEC file number is 001-37565.
When was NovoCure Limited incorporated or organized?
The filing states the company is organized under the laws of Jersey.
What other types of information are disclosed in this 8-K filing?
In addition to officer and director changes, the filing includes Regulation FD Disclosures and Financial Statements and Exhibits.
Filing Stats: 1,165 words · 5 min read · ~4 pages · Grade level 12.2 · Accepted 2025-12-01 07:01:24
Filing Documents
- nvcr-20251124.htm (8-K) — 32KB
- separationagreement.htm (EX-10.1) — 37KB
- testpr.htm (EX-99.1) — 9KB
- 0001645113-25-000045.txt ( ) — 206KB
- nvcr-20251124.xsd (EX-101.SCH) — 2KB
- nvcr-20251124_lab.xml (EX-101.LAB) — 21KB
- nvcr-20251124_pre.xml (EX-101.PRE) — 12KB
- nvcr-20251124_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 1, 2025, the Company issued a press release announcing the resignations of Ashley Cordova as a Director and Chief Executive Officer of the Company and the appointment of Frank Leonard as Chief Executive Officer. A copy of the press release is attached to this report as Exhibit 99.1. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Cordova Separation Agreement 99.1 Press Release of NovoCure Limited, dated December 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: December 1, 2025 By: /s/ Barak Ben-Arye Name: Barak Ben-Arye Title: General Counsel